Company intelligence / Profile preview

Oranda Therapeutics

Dublin, Dublin, Irelandorandatherapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Oranda Therapeutics is developing a novel medicine currently in Phase 2b for hyperphagia associated with Prader-Willi syndrome. The company plans to initiate a pivotal Phase 3 study in 2025. Additionally, it has secured rights to commercialize several established rare disease medicines, with the first launch expected in the first half of 2026. There are currently no approved therapies for PWS-related hyperphagia or behavioral symptoms.[2]

Therapeutic areas: Rare Diseases
Modalities: Small molecules (inferred from rare disease focus and pipeline, but not explicitly stated)[2]
Industry: Biotech

Beyond the preview

Go deeper on Oranda Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oranda Therapeutics.

Explore the full profile